BIIB Maintained by Barclays -- Price Target Raised to $230

gurufocus.com · 2026-10-28

Biogen Inc. Analyst Rating Update On October 28, 2026, Barclays maintained its Equal-Weight rating for Biogen (BIIB) while increasing the price target from $

TickrTrends take: Barclays raised its price target for BIIB to $230, signaling confidence in the company's prospects. However, TickrTrends currently assesses BIIB as overvalued, suggesting the market may already be pricing in optimistic expectations for this Healthcare sector company. Investors focused on valuation metrics should monitor whether the stock's trading price narrows the gap to Barclays' target or whether fundamentals support the elevated valuation assessment.

Read the full story at gurufocus.com →